Checkpoint Therapeutics (NASDAQ: CKPT) gained Monday, on word the company and GC Cell announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint’s anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s Immuncell-LC, an innovative autologous Cytokine Induced Killer T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.
This collaboration will initially focus on conducting in vitro combination studies to evaluate the synergistic effects of these two therapies on cancer cell destruction. Positive preliminary data from these studies could potentially pave the way for future in vivo research and clinical studies.
The anticipated synergy between cosibelimab’s antibody-dependent cellular cytotoxicity (“ADCC”) mechanism of action and Immuncell-LC’s robust autologous CIK T cell response is supported by extensive research. This combination is expected to leverage immune system components more effectively in targeting and eliminating cancer cells.
James Park, CEO of GC Cell, highlighted the agreement’s potential: “This collaboration is a pivotal step towards significant technological collaborations. The integration of cosibelimab’s clinical efficacy and safety profile with our Immuncell-LC could set new therapeutic standards in immuno-oncology. We are optimistic that this partnership will lead to effective commercial licensing or joint development in the future.”
CKPT shares picked up 22 cents, or 9.4%, to $2.57.